Effectiveness of a closed-system device in containing surface contamination with cyclophosphamide and ifosfamide in an i.v. admixture area.
Connor
Thomas H
TH
Robert A. Taft Laboratories, National Institute for Occupational Safety and Health (MS-C23), 4676 Columbia Parkway, Cincinnati, OH 45226, USA. twc6@cdc.gov
Anderson
Roger W
RW
Sessink
Paul J
PJ
Spivey
Susan M
SM
D000970:Antineoplastic Agents / Q000009:adverse effects*; D003520:Cyclophosphamide / Q000009:adverse effects*; D004784:Environmental Monitoring; D004867:Equipment Design; D005472:Fluorouracil / Q000009:adverse effects*; D006801:Humans; D007069:Ifosfamide / Q000009:adverse effects*; D007262:Infusions, Intravenous; D016273:Occupational Exposure / Q000517:prevention & control*; D010595:Pharmacists
D000970:Antineoplastic Agents; D003520:Cyclophosphamide; D005472:Fluorouracil; D007069:Ifosfamide